Mindmed provides corporate update and 2023 outlook

- company positioned for key mm-120 phase 2b data readout in gad and phase 2a data readout in adhd in late 2023 - company to initiate first clinical trial of mm-402 in 2023 - cash runway to fund current operating plan into first half of 2025 - company to host a virtual analyst and investor day in the first half of 2023 new york , jan. 9, 2023 /prnewswire/ -- mind medicine (mindmed) inc. (nasdaq: mnmd), (neo: mmed), (the "company" or "mindmed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today provided a corporate update and outlook for 2023. "following a year of continued strong execution, our progress in 2022 has set the stage for a meaningful 2023, a year in which we plan to further elucidate the potential of our mm-120 product candidate in generalized anxiety disorder (gad) and initiate the first clinical trial for our mm-402 program," stated rob barrow, chief executive officer.
MNMD Ratings Summary
MNMD Quant Ranking